We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Two blood pressure-lowering drug classes, called ACE inhibitors and ARBs, came under scrutiny after the US Centers for Disease Control and Prevention reported in April that 72 per cent of hospitalized COVID-19 patients 65 or older had hypertension.